0001104659-21-089325.txt : 20210706 0001104659-21-089325.hdr.sgml : 20210706 20210706141100 ACCESSION NUMBER: 0001104659-21-089325 CONFORMED SUBMISSION TYPE: 425 PUBLIC DOCUMENT COUNT: 2 FILED AS OF DATE: 20210706 DATE AS OF CHANGE: 20210706 SUBJECT COMPANY: COMPANY DATA: COMPANY CONFORMED NAME: ALEXION PHARMACEUTICALS, INC. CENTRAL INDEX KEY: 0000899866 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 133648318 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 425 SEC ACT: 1934 Act SEC FILE NUMBER: 000-27756 FILM NUMBER: 211073565 BUSINESS ADDRESS: STREET 1: 121 SEAPORT BOULEVARD CITY: BOSTON STATE: MA ZIP: 02210 BUSINESS PHONE: 4752302596 MAIL ADDRESS: STREET 1: 121 SEAPORT BOULEVARD CITY: BOSTON STATE: MA ZIP: 02210 FORMER COMPANY: FORMER CONFORMED NAME: ALEXION PHARMACEUTICALS INC DATE OF NAME CHANGE: 19960111 FILED BY: COMPANY DATA: COMPANY CONFORMED NAME: ASTRAZENECA PLC CENTRAL INDEX KEY: 0000901832 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 000000000 STATE OF INCORPORATION: X0 FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 425 BUSINESS ADDRESS: STREET 1: 1 FRANCIS CRICK AVENUE STREET 2: CAMBRIDGE BIOMEDICAL CAMPUS CITY: CAMBRIDGE STATE: X0 ZIP: CB2 0AA BUSINESS PHONE: 011 44 20 7304 5000 MAIL ADDRESS: STREET 1: 1 FRANCIS CRICK AVENUE STREET 2: CAMBRIDGE BIOMEDICAL CAMPUS CITY: CAMBRIDGE STATE: X0 ZIP: CB2 0AA FORMER COMPANY: FORMER CONFORMED NAME: ZENECA GROUP PLC DATE OF NAME CHANGE: 19930422 425 1 a21-21502_2425.htm 425

 

Filed by AstraZeneca PLC

This communication is filed pursuant to Rule 425

under the United States Securities Act of 1933

Subject Company: Alexion Pharmaceuticals, Inc.

(Commission File No. 000-27756)

Date: July 6, 2021

 

The following is an image of a table tracking competition clearances achieved in the proposed acquisition of Alexion and was updated by AstraZeneca PLC on its website on July 6, 2021, to reflect competition clearance achieved in the European Union:

 

GRAPHIC

 

Important additional information

 

In connection with AstraZeneca’s proposed acquisition of Alexion (the Acquisition), AstraZeneca filed a registration statement on Form F-4 with the SEC on 12 April 2021 (the Registration Statement), which has been declared effective by the United States Securities and Exchange Commission, and which includes a document that serves as a prospectus of AstraZeneca and a proxy statement of Alexion (the proxy statement/prospectus). Alexion filed a proxy statement with the SEC (the proxy statement) on 12 April 2021, and each party will file other documents regarding the Acquisition with the SEC. Investors and security holders of Alexion are urged to carefully read the entire Registration Statement and proxy statement/prospectus or proxy statement and other relevant documents filed with the SEC when they become available, because they will contain important information. Investors and security holders may obtain the Registration Statement and the proxy statement/prospectus or the proxy statement free of charge from the SEC’s website or from AstraZeneca or Alexion as described in the paragraphs below.

 

The documents filed by AstraZeneca with the SEC may be obtained free of charge at the SEC’s website at www.sec.gov. These documents may also be obtained free of charge on AstraZeneca’s website at http://www.astrazeneca.com under the tab “Investors”. The documents filed by Alexion with the SEC

 


 

may be obtained free of charge at the SEC’s website at www.sec.gov. These documents may also be obtained free of charge on Alexion’s internet website at http://www.alexion.com under the tab, “Investors” and under the heading “SEC Filings” or by contacting Alexion’s Investor Relations Department at investorrelations@alexion.com.

 

Forward-looking statements

 

This announcement contains certain forward-looking statements with respect to the operations, performance and financial condition of the AstraZeneca Group, including, among other things, statements about expected revenues, margins, earnings per share or other financial or other measures, as well as the ability of the parties to consummate the Acquisition on a timely basis or at all, the ability of the parties to satisfy the conditions precedent to consummation of the Acquisition, including the ability to secure the required regulatory approvals on the terms expected, at all or in a timely manner, the ability of AstraZeneca to successfully integrate Alexion’s operations, and the ability of AstraZeneca to implement its plans, forecasts and other expectations with respect to Alexion’s business after Completion and realise expected synergies. Although the AstraZeneca Group believes its expectations are based on reasonable assumptions, any forward-looking statements, by their very nature, involve risks and uncertainties and may be influenced by factors that could cause actual outcomes and results to be materially different from those predicted. The forward-looking statements reflect knowledge and information available at the date of preparation of this announcement and the AstraZeneca Group undertakes no obligation to update these forward-looking statements. The AstraZeneca Group identifies the forward-looking statements by using the words ‘anticipates’, ‘believes’, ‘expects’, ‘intends’ and similar expressions in such statements. Important factors that could cause actual results to differ materially from those contained in forward-looking statements, certain of which are beyond the AstraZeneca Group’s control, include, among other things: the risks set out in Part II (Risk Factors) of the AstraZeneca shareholder circular published on 12 April 2021; failure or delay in delivery of pipeline or launch of new medicines; failure to meet regulatory or ethical requirements for medicine development or approval; failure to obtain, defend and enforce effective intellectual property (IP) protection and IP challenges by third parties; competitive pressures including expiry or loss of IP rights, and generic competition; price controls and reductions; economic, regulatory and political pressures; uncertainty and volatility in relation to the UK’s exit from the EU; failures or delays in the quality or execution of commercial strategies; failure to maintain supply of compliant, quality medicines; illegal trade in medicines; reliance on third-party goods and services; failure in information technology, data protection or cybercrime; failure of critical processes; uncertainty of expected gains from productivity initiatives; failure to attract, develop, engage and retain a diverse, talented and capable workforce, including following Completion; failure to adhere to applicable laws, rules and regulations; the safety and efficacy of marketed medicines being questioned; adverse outcome of litigation and/or governmental investigations, including relating to the Acquisition; failure to adhere to increasingly stringent anti-bribery and anti-corruption legislation; failure to achieve strategic plans or meet targets or expectations; failure in financial control or the occurrence of fraud; unexpected deterioration in AstraZeneca’s or Alexion’s financial position; the impact that the COVID-19 global pandemic may have or continue to have on these risks, on AstraZeneca’s ability to continue to mitigate these risks, and on AstraZeneca’s operations, financial results or financial condition; the risk that a condition to the closing of the Acquisition may not be satisfied, or that a regulatory approval that may be required for the Acquisition is delayed or is obtained subject to conditions that are not anticipated; the risk that AstraZeneca is unable to achieve the synergies and value creation contemplated by the Acquisition, or that AstraZeneca is unable to promptly and effectively integrate Alexion’s businesses; and the risk that management’s time and attention are diverted on Acquisition-related issues or that disruption from the Acquisition makes it more difficult to maintain business, contractual and operational relationships.

 

Neither AstraZeneca nor any of its associates or directors, officers or advisers provides any representation, assurance or guarantee that the occurrence of the events expressed or implied in any forward-looking statements in this announcement will actually occur. You are cautioned not to place undue reliance on these

 


 

forward-looking statements. Other than in accordance with their legal or regulatory obligations (including under the Listing Rules, the Disclosure and Transparency Rules and the Prospectus Regulation Rules of the FCA), AstraZeneca is under no obligation, and AstraZeneca expressly disclaims any intention or obligation to update or revise publicly any forward-looking statements, whether as a result of new information, future events or otherwise.

 

AstraZeneca

 

AstraZeneca (LSE/STO/Nasdaq: AZN) is a global, science-led biopharmaceutical company that focuses on the discovery, development, and commercialisation of prescription medicines, primarily for the treatment of diseases in three therapy areas - Oncology, Cardiovascular, Renal & Metabolism, and Respiratory & Immunology. Based in Cambridge, UK, AstraZeneca operates in over 100 countries and its innovative medicines are used by millions of patients worldwide. Please visit astrazeneca.com and follow the Company on Twitter @AstraZeneca.

 


GRAPHIC 2 g215022bei001.gif GRAPHIC begin 644 g215022bei001.gif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end